 Home > Active Ingredient News > Antitumor Therapy > Prostate: What is the prognostic value of 11C-choline PET/CT in patients with metastatic castration-resistant prostate cancer?

Prostate: What is the prognostic value of 11C-choline PET/CT in patients with metastatic castration-resistant prostate cancer?

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

what function prostate

serum viscosity test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Prostate cancer is the most commonly diagnosed cancer in men.
Among the newly diagnosed cancers in the United States in 2019, there were 174650 cases (20%) and 31260 deaths
.

Localized prostate cancer can be cured by radical prostatectomy or radiotherapy

174650 31260

Recently, American researchers published an article in "Prostate", evaluating 11C-choline positron emission tomography/computed tomography (PET/CT) in metastatic castration-resistant prostate cancer undergoing docetaxel chemotherapy ( mCRPC) prognostic utility in patients
.

Assessed the prognostic utility of receiving docetaxel chemotherapy transfer of castration-resistant prostate cancer (mCRPC) patients with positron emission tomography / computed tomography (PET / CT) 11C- choline assessed 11C- choline positive The prognostic utility of electron emission tomography/computed tomography (PET/CT) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel chemotherapy

Researchers conducted a single-institution retrospective analysis of 77 mCRPC patients who received 6 cycles of docetaxel chemotherapy.
These patients were at baseline (before chemotherapy), mid-term (after 3 cycles), and after treatment (after 6 cycles).
) All received 11C-choline PET/CT scan
.

The treatment response was evaluated based on the percentage change of the maximum normalized uptake value (SUVmax) of the blood pool corrected by the lesion on PET/CT and the percentage change of serum prostate-specific antigen (PSA)

It was found that the percentage change in blood pool SUVmax in the interim scan was an important predictor of complete response (probability [OR]: 0.
98, 95% confidence interval [CI]: 0.
96-0.
99, P=0.
0003), while the percentage change in PSA was not Predictors of complete response (OR: 0.
99, 95% CI: 0.
99-1.
01, P=0.
6025)
.

Fifty-seven of the 77 patients (74%) had a reduction of SUVmax in the mid-term blood pool by ≥20%; compared with patients with a reduction in blood pool SUVmax of <20%, patients with a reduction of ≥20% completed 6 cycles of doceta After chemotherapy, the probability of complete response is 3.

The percentage change in blood pool SUVmax in the interim scan is an important predictor of complete response The percentage change in blood pool SUVmax in the interim scan is an important predictor of complete response

Univariate and multivariate analysis of blood pool SUVmax and PSA for predicting complete response

In summary, the 11C-choline PET/CT assessment of mCRPC patients receiving docetaxel chemotherapy in the middle of the treatment course and after the treatment course can predict the treatment response and PFS of the whole course of treatment, respectively
.

11C-choline PET/CT imaging can provide valuable prognostic information to guide the treatment options of mCRPC patients

The 11C-choline PET/CT assessment of mCRPC patients receiving docetaxel chemotherapy during the middle and after the treatment can predict the treatment response and PFS of the whole course of treatment, respectively

Original source:

Masaya Jimbo, Jack R Andrews, Mohamed E Ahmed et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.